Search
for
Sort by
Research 91–120 of 112
- Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches
- Effect of Sun exposure-induced ferroptosis mechanisms on pathology and potential biological processes of primary melanoma by microarray data analysis
- Targeted protein degradation of Wnt/β-catenin signaling pathway: an effective strategy for cancer therapy
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Autophagy: Guardian of Skin Barrier
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
- Genetic Tools for Cell Lineage Tracing and Profiling Developmental Trajectories in the Skin
- Advancing Design Strategy of PROTACs for Cancer Therapy
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Proteomics as a tool to improve novel insights into skin diseases: what we know and where we should be going
- RAGE and Its Ligands in Melanoma
- Human Pigmentation: A Review of Molecular Mechanisms, Genetic Architecture, Evolution, Forensic DNA Phenotyping and Health Implications
- Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Re‐Innovation in Clinical Trial Designs Based on Precision Therapy
- Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
- Melanocytes in regenerative medicine applications and disease modeling
- Reexamining the Role of Diet in Dermatology
- Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020
- Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- Author response: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- Editor's evaluation: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
- Decision letter: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma